Published in Br J Cancer on January 23, 2007
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine (2008) 2.48
Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ (2007) 1.72
Modeling cervical cancer prevention in developed countries. Vaccine (2008) 1.61
The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer (2007) 1.45
Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr (2007) 1.39
Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med (2009) 1.29
Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine (2012) 1.08
Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PLoS One (2014) 1.06
An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol (2014) 0.99
Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2007) 0.96
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol (2015) 0.92
Predictors of three dose on-time compliance with HPV4 vaccination in a disadvantaged, underserved, safety net population in the US Midwest. PLoS One (2013) 0.87
Identification of sex-associated network patterns in Vaccine-Adverse Event Association Network in VAERS. J Biomed Semantics (2015) 0.87
Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2010) 0.86
Mathematical modeling and the epidemiological research process. Eur J Epidemiol (2009) 0.82
Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infect Agent Cancer (2014) 0.81
Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries. Infect Dis Obstet Gynecol (2011) 0.81
Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program. BMC Infect Dis (2014) 0.81
Evaluating human papillomavirus vaccination programs in Canada: should provincial healthcare pay for voluntary adult vaccination? BMC Public Health (2008) 0.79
Quantifying clinical HPV4 dose inefficiencies in a safety net population. PLoS One (2013) 0.77
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med (1998) 11.61
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
The epidemiology of genital human papillomavirus infection. Vaccine (2006) 3.28
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Evaluating human papillomavirus vaccination programs. Emerg Infect Dis (2004) 2.47
Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med (2006) 2.10
Cervical cancer, human papillomavirus, and vaccination. BMJ (2005) 1.43
An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect (2002) 1.40
Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol (2003) 1.20
No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer (1999) 0.97
Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer (2006) 0.96
Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer (2004) 0.91
Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med (2000) 25.49
Heterogeneities in the transmission of infectious agents: implications for the design of control programs. Proc Natl Acad Sci U S A (1997) 9.07
Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet (1998) 6.94
Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer (1999) 6.73
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer (2006) 6.59
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33
Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet (2001) 6.23
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA (2001) 5.99
Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol (1994) 4.89
A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis (2001) 4.73
Improved data, methods and tools for the 2007 HIV and AIDS estimates and projections. Sex Transm Infect (2008) 3.38
Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A (2001) 3.31
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Coeliac disease--associated disorders and survival. Gut (1994) 3.13
Aggressiveness of screen-detected breast cancers. Lancet (1995) 3.07
HIV infection and reproductive health in teenage women orphaned and made vulnerable by AIDS in Zimbabwe. AIDS Care (2005) 2.89
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med (1999) 2.79
The role of sexual partnership networks in the epidemiology of gonorrhea. Sex Transm Dis (1997) 2.69
Survival of cancer patients in Finland 1955-1994. Acta Oncol (1999) 2.67
Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. Sex Transm Infect (2006) 2.65
Reductions in risk behaviour provide the most consistent explanation for declining HIV-1 prevalence in Uganda. AIDS (1999) 2.61
The spread of HIV-1 in Africa: sexual contact patterns and the predicted demographic impact of AIDS. Nature (1991) 2.55
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Strategies for global control of cervical cancer. Int J Cancer (1995) 2.52
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (1986) 2.42
Effectiveness of the public health policy for breast cancer screening in Finland: population based cohort study. BMJ (1997) 2.41
Mathematical models of the transmission and control of sexually transmitted diseases. Sex Transm Dis (2000) 2.41
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
Social class as a prognostic factor in breast cancer survival. Cancer (1990) 2.37
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Risk of cancer in Finnish children living close to power lines. BMJ (1993) 2.29
Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology (2000) 2.25
Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry (2001) 2.23
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Behaviour change in generalised HIV epidemics: impact of reducing cross-generational sex and delaying age at sexual debut. Sex Transm Infect (2007) 2.09
Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol (2000) 2.09
From cross-tabulations to multipurpose exposure information systems: a new job-exposure matrix. Am J Ind Med (1998) 2.07
Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut (2005) 2.07
Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med (1997) 2.06
Progression of asbestosis predicts lung cancer. Chest (1998) 2.02
Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst (1995) 2.01
Risks of acquiring and transmitting sexually transmitted diseases in sexual partner networks. Sex Transm Dis (2000) 2.00
The effectiveness of HIV prevention and the epidemiological context. Bull World Health Organ (2001) 1.98
Recent adverse trends in semen quality and testis cancer incidence among Finnish men. Int J Androl (2011) 1.96
Indoor radon exposure and risk of lung cancer: a nested case-control study in Finland. J Natl Cancer Inst (1996) 1.93
BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A (1988) 1.91
Tuberculosis screening of migrants to low-burden nations: insights from evaluation of UK practice. Eur Respir J (2010) 1.88
Multiple cancer--an epidemiologic exercise in Finland. J Natl Cancer Inst (1985) 1.87
Demographic impact of the HIV epidemic in Thailand. AIDS (1998) 1.86
Comparison of performances of two commercially available tests, a PCR assay and a ligase chain reaction test, in detection of urogenital Chlamydia trachomatis infection. J Clin Microbiol (1998) 1.85
Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ Health Perspect (1999) 1.84
Work-related cancer in the Nordic countries. Scand J Work Environ Health (1999) 1.84
Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol (1999) 1.84
Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol (1995) 1.84
Low-efficacy HIV vaccines: potential for community-based intervention programmes. Lancet (1996) 1.83
Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol (1999) 1.83
Sexual partner networks in the transmission of sexually transmitted diseases. An analysis of gonorrhea cases in Sheffield, UK. Sex Transm Dis (1997) 1.82
Chlamydial endometritis. J Clin Pathol (1985) 1.80
More realistic models of sexually transmitted disease transmission dynamics: sexual partnership networks, pair models, and moment closure. Sex Transm Dis (2000) 1.78
Gynaecological infections as risk determinants of subsequent cervical neoplasia. Acta Oncol (2000) 1.71
Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol (2005) 1.70
Chlamydia trachomatis seroprevalence atlas of Finland 1983-2003. Sex Transm Infect (2007) 1.69
Revealing the history of infectious disease epidemics through phylogenetic trees. Philos Trans R Soc Lond B Biol Sci (1995) 1.65
Microbiological and histopathological findings in acute pelvic inflammatory disease. Br J Obstet Gynaecol (1987) 1.65
Malignancies in cases with screening-identified evidence of coeliac disease: a long-term population-based cohort study. Gut (2008) 1.64
Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med (1999) 1.63
Serum CA 125 in acute pelvic inflammatory disease. Br J Obstet Gynaecol (1989) 1.62
Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet (2005) 1.61
Trends in cancer incidence in the Nordic countries. A collaborative study of the five Nordic Cancer Registries. Acta Pathol Microbiol Immunol Scand Suppl (1986) 1.60
Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer (2000) 1.59
Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer (2000) 1.58
Cancer incidence among 78,000 asthmatic patients. Int J Epidemiol (1993) 1.58
Elevated lung cancer risk among persons with depressed mood. Am J Epidemiol (1996) 1.58
Cancer incidence among Finnish workers exposed to halogenated hydrocarbons. J Occup Environ Med (1995) 1.56
Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer (1999) 1.56
Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol (1997) 1.56
Magnetic fields of high voltage power lines and risk of cancer in Finnish adults: nationwide cohort study. BMJ (1996) 1.55
Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ (1997) 1.55
Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst (2000) 1.54
A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect (2005) 1.54
Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res (2003) 1.54
Sampling biases and missing data in explorations of sexual partner networks for the spread of sexually transmitted diseases. Stat Med (1998) 1.53
A rural HIV epidemic in Zimbabwe? Findings from a population-based survey. Int J STD AIDS (2001) 1.53
Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer (1995) 1.52
Trichomonas vaginalis epidemiology: parameterising and analysing a model of treatment interventions. Sex Transm Infect (2000) 1.49
Selective screening: theory and practice based on high-risk groups of cervical cancer. J Epidemiol Community Health (1979) 1.48